Published • loading... • Updated
Cipla InvaGen Facility Gets VAI Status From USFDA
Summary by equitypandit.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cipla InvaGen Facility Gets VAI Status From USFDA
Cipla has disclosed that the USFDA classified its InvaGen New York plant inspection as Voluntary Action Indicated, closing the regulatory review. The plant is Unit 3 of InvaGen Pharmaceuticals, located in Central Islip, New York. InvaGen is a wholly owned Cipla subsidiary that manufactures generic drugs for the US market.... The post Cipla InvaGen Facility Gets VAI Status From USFDA appeared first on Equitypandit.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
